Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Octimibate (Octimibato) 是一种非前列腺素类血小板聚集抑制剂和环前列腺素激动剂。Octimibate 可用于治疗心血管疾病,可用于研究动脉粥样硬化和血栓形成。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,000 | 现货 | ||
5 mg | ¥ 2,500 | 现货 | ||
10 mg | ¥ 3,730 | 现货 | ||
25 mg | ¥ 5,890 | 现货 | ||
50 mg | ¥ 8,290 | 现货 | ||
100 mg | ¥ 11,200 | 现货 | ||
500 mg | ¥ 22,300 | 现货 |
产品描述 | Octimibate (Octimibato) is a non-prostaglandin platelet aggregation inhibitor and cyclic prostaglandin agonist.Octimibate is used in the treatment of cardiovascular disease and can be used to study atherosclerosis and thrombosis. |
体外活性 |
In suspensions of washed (plasma-free) human platelets, octimibate is a potent inhibitor of aggregation; its IC50 is approx 10 nM for inhibition of aggregation is stimulated by several different agonists, including U46619 and ADP. The inhibitory effects of octimibate on aggregation are not competitive with the stimulatory agonist; the maximal response is suppressed but there is no obvious shift in potency of the agonist. In platelet-rich plasma, octimibate inhibits agonist-stimulated aggregation with an IC50 of approx 200 nM.[2] Octimibate increases cyclic AMP concentrations in platelets and increases the cyclic AMP-dependent protein kinase activity ratio. Octimibate stimulates adenylyl cyclase activity in human platelet membranes, with an EC50 of 200 nM. The maximal achievable activation of adenylyl cyclase by intimidate is 60% of that obtainable with iloprost. Octimibate has no effect on the cyclic GMP-inhibited phosphodiesterase (phosphodiesterase-ITI), which is the major cyclic AMP-degrading enzyme in human platelets.[2] |
别名 | Octimibato |
分子量 | 454.56 |
分子式 | C29H30N2O3 |
CAS No. | 89838-96-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (110 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1999 mL | 10.9996 mL | 21.9993 mL | 54.9982 mL |
5 mM | 0.44 mL | 2.1999 mL | 4.3999 mL | 10.9996 mL | |
10 mM | 0.22 mL | 1.1 mL | 2.1999 mL | 5.4998 mL | |
20 mM | 0.11 mL | 0.55 mL | 1.1 mL | 2.7499 mL | |
50 mM | 0.044 mL | 0.22 mL | 0.44 mL | 1.1 mL | |
100 mM | 0.022 mL | 0.11 mL | 0.22 mL | 0.55 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Octimibate 89838-96-0 GPCR/G Protein Immunology/Inflammation Prostaglandin Receptor Octimibato Inhibitor inhibitor inhibit